What is Qureight?
Qureight operates as a Core Imaging Laboratory, leveraging artificial intelligence to expedite drug development processes. The company specializes in AI-powered data curation, with a particular focus on lung and heart diseases. By partnering with biopharmaceutical companies, Contract Research Organizations (CROs), and hospitals, Qureight enhances the efficiency and effectiveness of clinical trials. Their proprietary technology facilitates the collaborative analysis of imaging, clinical data, and biomarkers, transforming complex healthcare data into real-time structured information for pharmaceutical clients. Qureight's core objective is to redefine precision medicine by extracting critical insights from intricate healthcare datasets using sophisticated AI analytics.
How much funding has Qureight raised?
Qureight has raised a total of $10.5M across 2 funding rounds:
Angel/Seed
$2M
Series A
$8.5M
Angel/Seed (2022): $2M with participation from Playfair Capital, Meltwind, Cambridge Angels, and Ascension
Series A (2024): $8.5M led by Playfair Capital, Guinness Global Investors, and Hargreave Hale AIM VCT
Key Investors in Qureight
Playfair Capital
Playfair Capital is a London-based venture capital firm specializing in pre-seed investments across the UK and Europe. They focus on visionary founders and aim to build strong foundations for growth, with a high graduation rate from pre-seed to Series A.
Guinness Global Investors
Guinness Global Investors, headquartered in London, is an investment banking firm providing financial services and investment management solutions with expertise in global investment strategies across various asset classes.
Hargreave Hale AIM VCT
Hargreave Hale AIM VCT is a diversified venture capital trust investing in small, high-growth UK companies, primarily on AIM, offering investors diversified portfolios and potential capital appreciation with attractive tax reliefs.
What's next for Qureight?
With its recent major strategic investment, Qureight is poised for significant growth and market expansion. The company's focus on AI-driven data curation for drug development, particularly in critical areas like lung and heart diseases, positions it favorably within the rapidly evolving biopharmaceutical landscape. This capital will likely be deployed to scale its technological infrastructure, expand its research and development capabilities, and broaden its client base. Qureight's ability to provide real-time structured data from complex imaging and clinical information is a key differentiator, enabling more precise and efficient drug discovery and development pathways. The company's trajectory suggests a continued emphasis on innovation and strategic partnerships to solidify its leadership in AI-powered precision medicine.
See full Qureight company page
